Studying good cholesterol function in type 1 diabetes with kidney disease
Compares blood and urine samples in adults with type 1 diabetes and kidney disease.
Key facts
- Who runs it
- Centre Hospitalier Universitaire Dijon
- Where
- Dijon, FranceSee the site
- Trial code
- Registry title
- Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 24 Apr 2018
- Expected to end
- Oct 2027
- Type of study
- Observational, 5 groups
- Treatments tested
- Blood samples
- Urine sample
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 1 diabetes, with or without kidney damage (protein in the urine), and adults without diabetes as a comparison group. Blood and urine samples are taken.
- Age
- Over 18 years
- Sex
- Men and women
- Disease stage
- Type 1 diabetes with normal albumin in the urine, with microalbuminuria, or with macroalbuminuria. Kidney filtration rate over 90 mL/min/1.73m2 (over 45 for macroalbuminuria). A comparison group has no diabetes.
- Earlier treatment
- Cannot take drugs that affect fats in the blood, other than insulin for type 1 diabetes.
- Biomarker or test result
- Type 1 diabetes patients: HbA1c between 6 and 9% (42–75 mmol/mol). Albumin in the urine as described for each group. Comparison group: fasting blood glucose under 6.10 mmol/L (110 mg/dL), triglycerides under 1.7 mmol/L (151 mg/dL), HDL cholesterol over 1.30 mmol/L (50 mg/dL) for women and 1.03 mmol/L (40 mg/dL) for men.
Main reasons for not taking part
- Protected adult
- Not covered by a social security scheme
- Pregnant or breastfeeding woman
- Taking drugs that interfere with fat metabolism, such as corticosteroids, estroprogestogens, retinoic acid or antiproteases
- BMI over 30 kg/m2
The registry criteria, word for word
Show all 30 criteriaShow less
Who can take part
- age > 18 years
- a person who has given oral consent
- Non-diabetics
- Fasting plasma glucose < 6.10 mmol/L (1.1 g/L)
- Triglyceridemia < 1.7 mmol/L (1.5 g/l)
- HDL-C concentration > 1.30 mmol/L (for women and 1.03 mmol/L for men)
- Glomerular filtration flow rate > 90 mL/min/1.73m2 (These thresholds correspond to the standard thresholds for these parameters)
- age > 18 years
- a person who has given oral consent
- Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
- HbA1c between 6 and 9%
- normal albuminuria (albumin/creatinine ratio < 2.5 mg/mmol in men and < 3.5 in women)
- glomerular filtration rate > 90 mL/min/1.73m2
- age > 18 years
- a person who has given oral consent
- Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
- HbA1c between 6 and 9%
- Microalbuminuria (albumin/creatinine ratio > 2.5 mg/mmol in men and > 3.5 in women, and < 30 mg/mmol)
- glomerular filtration rate > 90 mL/min/1.73m2
- age > 18 years
- a person who has given oral consent
- Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l)
- HbA1c between 6 and 9%
- Macroalbuminuria (albumin/creatinine ratio > 30 mg/mmol)
- glomerular filtration rate > 45 mL/min/1.73m2
Who cannot take part
- Drugs interfering with lipid metabolism outside insulin for DT1 : hypolipidemic (only for patients included in the DT1-micro group), corticosteroid, estroprogestogens, retinoic acid, antiproteases
- Protected adult
- Patient not affiliated to a social security scheme
- Pregnant or breastfeeding woman
- BMI > 30 kg/m2
Where in France
- Chu Dijon BourogneDijon, FranceContact: Laurence DUVILLARDTaking people
About the trial
What the trial wants to find out
A number of arguments suggest that the deterioration in high density lipoproteins (HDL) functioning may worsen with the development of nephropathy during type 1 diabetes (T1D).
Read full original descriptionShow less
The objective of this study will be to investigate to what extent nephropathy in T1D patients in the microalbuminuria and macroalbuminuria stages, compared to T1D patients without nephropathy, is associated with an alteration in HDL functionality and changes in HDL size and composition (lipids with detailed study of phosphates and sphingolipids, main lipoproteins, inflammatory markers).
The 5 groups in the trial
- control
Treatment: Blood samples and Urine sample
- T1D with normal albumin levels
Treatment: Blood samples and Urine sample
- T1D with macroalbuminuria
Treatment: Blood samples and Urine sample
- T1D with microalbuminuria
Treatment: Blood samples and Urine sample
- T1D with microalbuminuria and statins
Treatment: Blood samples and Urine sample
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy
- Plain-language title
- Studying good cholesterol function in type 1 diabetes with kidney diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 October 2026